This company has been acquired
La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !
TCR2 Therapeutics Résultats passés
Passé contrôle des critères 0/6
TCR2 Therapeutics's earnings have been declining at an average annual rate of -16%, while the Biotechs industry saw earnings growing at 32.7% annually.
Informations clés
-16.0%
Taux de croissance des bénéfices
87.3%
Taux de croissance du BPA
Biotechs Croissance de l'industrie | 17.0% |
Taux de croissance des recettes | n/a |
Rendement des fonds propres | -161.0% |
Marge nette | n/a |
Dernière mise à jour des bénéfices | 31 Mar 2023 |
Mises à jour récentes des performances passées
Pas de mise à jour
Recent updates
Here's Why TCR2 Therapeutics (NASDAQ:TCRR) Must Use Its Cash Wisely
Mar 08Can TCR2 Therapeutics (NASDAQ:TCRR) Afford To Invest In Growth?
Nov 23TCR² Therapeutics: Betting On A Solid Reversal
Aug 18TCR2 Therapeutics GAAP EPS of -$0.82 misses by $0.02
Aug 08We Think TCR2 Therapeutics (NASDAQ:TCRR) Needs To Drive Business Growth Carefully
Jun 08We Think TCR2 Therapeutics (NASDAQ:TCRR) Can Afford To Drive Business Growth
Jan 11TCR2 Therapeutics: Trading Below Cash
Jan 06TCR2 Therapeutics: Trading Near Cash Value
Oct 12Is There An Opportunity With TCR2 Therapeutics Inc.'s (NASDAQ:TCRR) 26% Undervaluation?
Sep 02TCR2 Therapeutics - Promising Technology And Upside Potential
Jun 15Companies Like TCR2 Therapeutics (NASDAQ:TCRR) Are In A Position To Invest In Growth
Jun 04Who Has Been Selling TCR2 Therapeutics Inc. (NASDAQ:TCRR) Shares?
Feb 19TCR2 Therapeutics (NASDAQ:TCRR) Is In A Good Position To Deliver On Growth Plans
Dec 28TCR2 Therapeutics share slumps 11%, announces response for Phase 1/2 Trial of TC-210
Dec 14TCR2 Therapeutics reports Q3 results
Nov 12TCR² Therapeutics teams up with ElevateBio to expand TC-210 manufacturing capacity
Nov 10Ventilation des recettes et des dépenses
Comment TCR2 Therapeutics gagne et dépense de l'argent. Sur la base des derniers bénéfices déclarés, sur une base LTM.
Historique des gains et des recettes
Date | Recettes | Les revenus | Dépenses G+A | Dépenses de R&D |
---|---|---|---|---|
31 Mar 23 | 0 | -163 | 41 | 91 |
31 Dec 22 | 0 | -152 | 39 | 84 |
30 Sep 22 | 0 | -119 | 38 | 77 |
30 Jun 22 | 0 | -115 | 39 | 72 |
31 Mar 22 | 0 | -107 | 39 | 65 |
31 Dec 21 | 0 | -100 | 37 | 59 |
30 Sep 21 | 0 | -91 | 34 | 57 |
30 Jun 21 | 0 | -81 | 32 | 50 |
31 Mar 21 | 0 | -73 | 25 | 49 |
31 Dec 20 | 0 | -67 | 22 | 46 |
30 Sep 20 | 0 | -61 | 22 | 42 |
30 Jun 20 | 0 | -58 | 18 | 43 |
31 Mar 20 | 0 | -53 | 20 | 37 |
31 Dec 19 | 0 | -97 | 18 | 33 |
30 Sep 19 | 0 | -96 | 16 | 31 |
30 Jun 19 | 0 | -100 | 13 | 25 |
31 Mar 19 | 0 | -107 | 11 | 22 |
31 Dec 18 | 0 | -62 | 9 | 17 |
30 Sep 18 | 0 | -55 | 9 | 13 |
31 Dec 17 | 0 | -15 | 5 | 8 |
Des revenus de qualité: TCRR is currently unprofitable.
Augmentation de la marge bénéficiaire: TCRR is currently unprofitable.
Analyse des flux de trésorerie disponibles par rapport aux bénéfices
Analyse de la croissance passée des bénéfices
Tendance des revenus: TCRR is unprofitable, and losses have increased over the past 5 years at a rate of 16% per year.
Accélération de la croissance: Unable to compare TCRR's earnings growth over the past year to its 5-year average as it is currently unprofitable
Bénéfices par rapport au secteur d'activité: TCRR is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-25.4%).
Rendement des fonds propres
ROE élevé: TCRR has a negative Return on Equity (-160.96%), as it is currently unprofitable.